Research programme: mesenchymal stromal cell therapy - Avalon GloboCare
Alternative Names: CB-MSC-1; MSCLatest Information Update: 16 Oct 2020
At a glance
- Originator Avalon GloboCare
- Class Exosome therapies; Stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical COVID 2019 infections; Graft-versus-host disease
Most Recent Events
- 01 Oct 2020 Avalon GloboCare plans a phase I trial for Graft versus host disease in USA in the in the fourth quarter of 2020
- 01 Oct 2020 Avalon GloboCare plans a clinical trial for Acute graft-versus-host disease as a topical treatment
- 01 Oct 2020 Avalon GloboCare plans a clinical trial for Acute respiratory distress syndrome in the fourth quarter of 2020